Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
| Autor: | Ramireddy Bommireddy, Shannon Stone, Noopur Bhatnagar, Pratima Kumari, Luis E. Munoz, Judy Oh, Ki-Hye Kim, Jameson T. L. Berry, Kristen M. Jacobsen, Lahcen Jaafar, Swe-Htet Naing, Allison N. Blackerby, Tori Van der Gaag, Chloe N. Wright, Lilin Lai, Christopher D. Pack, Sampath Ramachandiran, Mehul S. Suthar, Sang-Moo Kang, Mukesh Kumar, Shaker J. C. Reddy, Periasamy Selvaraj |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Vaccines, Vol 10, Iss 6, p 944 (2022) |
| Druh dokumentu: | article |
| ISSN: | 10060944 2076-393X |
| DOI: | 10.3390/vaccines10060944 |
| Popis: | Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|